fenofibric acid has been researched along with benzoxazoles in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anai, M; Gonzalez, FJ; Ikeda, K; Inagaki, T; Kodama, T; Matsumura, Y; Raza-Iqbal, S; Sakai, J; Taguchi, A; Tanaka, T | 1 |
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
2 other study(ies) available for fenofibric acid and benzoxazoles
| Article | Year |
|---|---|
Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.
Topics: Animals; Benzoxazoles; Butyrates; Cell Culture Techniques; Cluster Analysis; Fenofibrate; Gene Expression Profiling; Hepatocytes; Humans; Hypolipidemic Agents; Liver; Mice; Tissue Culture Techniques; Transcriptome | 2015 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |